3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Ovarian Neoplasms
1
Neoplasms, Squamous Cell
1
Melanoma
1
Esophageal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
pembrolizumab
18
Nivolumab
7
Carboplatin
7
durvalumab
5
Ipilimumab
5
aldesleukin
4
Paclitaxel
4
Irinotecan
4
Gemcitabine
4
Docetaxel
4
Cisplatin
4
sargramostim
3
atezolizumab
3
Topotecan
3
Polymerase Chain Reaction
3
Magnetic Resonance Spectroscopy
3
temsirolimus
2
talazoparib
2
carfilzomib
2
cabozantinib
2
budigalimab
2
Trastuzumab
2
Therapeutics
2
Taxes
2
Specimen Handling
2
Psychiatric Rehabilitation
2
Injections
2
Gene Expression Profiling
2
Fulvestrant
2
Fluorodeoxyglucose F18
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Small Cell Lung Carcinoma
×
High-Intensity Focused Ultrasound Ablation
×
Gynecologic
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled